文献速递心力衰竭与心肌病

糖尿病无ASCVD成人心衰风险预测与预防的最佳筛查策略:汇总队列分析

Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis.
PubMed 文献 · Circulation · 2023-11-11

本研究汇总7个社区队列中无心衰的糖尿病成人,评估在无ASCVD人群中使用风险评分、生物标志物和超声心动图等一步或两步筛查策略识别心衰高风险者的效果。结果显示基于WATCH-DM评分选择性检测NT-proBNP能高效识别从SGLT2i预防心衰中绝对获益显著的高危一级预防人群。

要点

  • 无ASCVD的糖尿病患者5年心衰发生率为6.2%。
  • 一步筛查高危者5年NNT较低,但低危者中仍发生大量心衰事件。
  • WATCH-DM/NT-proBNP两步筛查成本最低且效果相当。

核心结论

  • 基于WATCH-DM评分选择性检测NT-proBNP可高效识别无ASCVD的糖尿病高危人群,该人群预期从SGLT2i预防心衰中获得显著绝对获益。

研究设计与样本

  • 汇总7个社区队列中基线无心衰的糖尿病成人,初始队列6293人(48.2%女性),其中77.7%无ASCVD者接受不同心衰筛查策略评估。

主要发现

  • 无ASCVD参与者5年随访时6.2%发生新发心衰。
  • 无ASCVD参与者中用SGLT2i预防1例心衰事件的5年NNT为43(95%CI 29-72)。
  • 一步筛查策略识别的高危者5年NNT较低(NT-proBNP为22,echo-DbCM为37),但低危者中仍发生大量心衰事件(echo-DbCM为29%,hs-cTn为47%)。
  • 两步筛查策略在高危亚组中捕获大部分心衰事件(75-89%),5年NNT与一步筛查相当(30-32)。

关键数值与推荐

  • WATCH-DM风险评分≥12定义为高危。
  • NT-proBNP≥125 pg/mL定义为高危。
  • hs-cTnT≥14 ng/L或hs-cTnI≥31 ng/L定义为高危。
  • echo-DbCM定义为左房扩大、左室肥厚或舒张功能障碍。

临床怎么用

  • 在无ASCVD的糖尿病患者中,可先使用WATCH-DM评分,对评分≥12者检测NT-proBNP以识别从SGLT2i预防心衰中绝对获益显著的高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal approach to identify individuals with diabetes who are at a high risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). METHODS: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high risk for developing HF were identified using 1-step screening strategies: risk score (WATCH-DM [Weight, Age, Hypertension, Creatinine, HDL-C, Diabetes Control, QRS Duration, MI, and CABG] ≥12), NT-proBNP (N-terminal pro-B-type natriuretic peptide ≥125 pg/mL), hs-cTn (high-sensitivity cardiac troponin T ≥14 ng/L; hs-cTnI ≥31 ng/L), and echocardiography-based diabetic cardiomyopathy (echo-DbCM; left atrial enlargement, left ventricular hypertrophy, or diastolic dysfunction). High-risk participants were also identified using 2-step screening strategies with a second test to identify residual risk among those deemed low risk by the first test: WATCH-DM/NT-proBNP, NT-proBNP/hs-cTn, NT-proBNP/echo-DbCM. Across screening strategies, the proportion of HF events identified, 5-year number needed to treat and number needed to screen to prevent 1 HF event with an SGLT2i (sodium-glucose cotransporter 2 inhibitor) among high-risk participants, and cost of screening were estimated. RESULTS: The initial study cohort included 6293 participants (48.2% women), of whom 77.7% without prevalent ASCVD were evaluated with different HF screening strategies. At 5-year follow-up, 6.2% of participants without ASCVD developed incident HF. The 5-year number needed to treat to prevent 1 HF event with an SGLT2i among participants without ASCVD was 43 (95% CI, 29-72). In the cohort without ASCVD, high-risk participants identified using 1-step screening strategies had a low 5-year number needed to treat (22 for NT-proBNP to 37 for echo-DbCM). However, a substantial proportion of HF events occurred among participants identified as low risk using 1-step screening approaches (29% for echo-DbCM to 47% for hs-cTn). Two-step screening strategies captured most HF events (75-89%) in the high-risk subgroup with a comparable 5-year number needed to treat as the 1-step screening approaches (30-32). The 5-year number needed to screen to prevent 1 HF event was similar across 2-step screening strategies (45-61). However, the number of tests and associated costs were lowest for WATCH-DM/NT-proBNP ($1061) compared with other 2-step screening strategies (NT-proBNP/hs-cTn: $2894; NT-proBNP/echo-DbCM: $16 358). CONCLUSIONS: Selective NT-proBNP testing based on the WATCH-DM score efficiently identified a high-risk primary prevention population with diabetes expected to derive marked absolute benefits from SGLT2i to prevent HF.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Patel, Segar, Klonoff, et al. Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis. Circulation. 2023. PMID: 37950893. doi:10.1161/CIRCULATIONAHA.123.067530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。